Concepedia

Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus

Sébastien Chanoine, Elodie Gautier‐Veyret, Hélène Pluchart, Julia Tonini, Xavier Fonrose, Johanna Claustre, Pierrick Bedouch, Françoise Stanke‐Labesque

British Journal of Clinical Pharmacology · 2020 · 13 citations · 22 references

DOIFull text

Open access

Abstract

The greater PCZ exposure achieved during PCZ-tab treatment increased drug-drug interactions with TAC and EVR, resulting in greater exposure, potentially exposing patients to higher risks of adverse effects.

References

22

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

Frédéric Tissot, Samir Agrawal, Livio Pagano et al. · Haematologica · 2016 · 661 citations · Full text

Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

Pierre Wallemacq, Victor W. Armstrong, Merçè Brunet et al. · Therapeutic Drug Monitoring · 2009 · 453 citations

, , +22

Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Thomas F. Patterson, George R. Thompson, David W. Denning et al. · Clinical Infectious Diseases · 2016 · 368 citations · Full text

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

Oliver A. Cornely, Rafael F. Duarte, Shariq Haider et al. · Journal of Antimicrobial Chemotherapy · 2015 · 167 citations · Full text

Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP

Vincent J. Lempers, Jeroen J. M. W. van den Heuvel, Frans G. M. Rüssel et al. · Antimicrobial Agents and Chemotherapy · 2016 · 99 citations · Full text

, , +14